Australia Markets open in 7 hrs 11 mins

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2279+0.0203 (+9.78%)
As of 11:47AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.2076
Open0.2097
Bid0.2230 x 2900
Ask0.2282 x 800
Day's range0.2097 - 0.2350
52-week range0.1310 - 2.4000
Volume148,020
Avg. volume312,318
Market cap6.377M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-5.8000
Earnings date15 May 2023 - 19 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

    First subject enrolled into the OPMD clinical development programHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q

  • GlobeNewswire

    Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

    HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) S

  • GlobeNewswire

    Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

    HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S.